- Report
- October 2025
- 198 Pages
Global
From €3186EUR$3,545USD£2,794GBP
€3540EUR$3,939USD£3,105GBP
- Report
- August 2025
- 186 Pages
Global
From €3186EUR$3,545USD£2,794GBP
€3540EUR$3,939USD£3,105GBP
- Report
- September 2025
- 250 Pages
Global
From €4036EUR$4,490USD£3,539GBP
- Report
- September 2025
- 250 Pages
Global
From €4036EUR$4,490USD£3,539GBP
- Report
- November 2025
- 282 Pages
Global
From €5258EUR$5,850USD£4,611GBP
- Report
- July 2021
- 50 Pages
China
From €2337EUR$2,600USD£2,049GBP
- Report
- July 2024
- 105 Pages
Global
From €4269EUR$4,750USD£3,744GBP
- Report
- May 2024
- 131 Pages
Global
From €4965EUR$5,524USD£4,354GBP
€5841EUR$6,499USD£5,123GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$4,171USD£3,177GBP
- Report
- February 2024
- 93 Pages
Global
From €3500EUR$4,171USD£3,177GBP
- Report
- November 2025
- 50 Pages
Global
From €2382EUR$2,650USD£2,089GBP
- Report
- March 2025
- 109 Pages
China
From €1618EUR$1,800USD£1,419GBP
- Report
- March 2025
- 215 Pages
China
From €3595EUR$4,000USD£3,153GBP

Nifedipine is a calcium channel blocker used to treat high blood pressure and angina. It is a commonly prescribed cardiovascular drug, and is available in both immediate-release and extended-release formulations. Nifedipine is also used to treat preterm labor, Raynaud's phenomenon, and hypertrophic cardiomyopathy. It is generally well-tolerated, but can cause side effects such as headache, dizziness, and swelling.
Nifedipine is available in both generic and brand-name formulations. Brand-name formulations include Procardia, Adalat, and Nifediac. Generic formulations are available from a variety of manufacturers.
In the Nifedipine market, some of the major players include Pfizer, Bayer, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more